Opinion
Video
Important Updates in the Management of Uncomplicated UTIs
Panelists discuss how American Urological Association (AUA) guidelines for recurrent uncomplicated urinary tract infections (UTIs) in women recommend culture-confirmed diagnosis, prophylactic antibiotics, nonantibiotic prevention, self-initiated treatment, and behavioral modifications while noting pivmecillinam’s recent FDA approval. Pivmecillinam features a penicillin-binding protein 2 inhibition mechanism with 85% to 95% efficacy against gram-negative uropathogens, including extended-spectrum β-lactamase producers; minimal intestinal flora disruption; low resistance rates; and primarily mild gastrointestinal adverse effects.
Video content above is prompted by the following:
- Summarize the current AUA guideline recommendations in managing recurrent uncomplicated UTIs in women.
- Pivmecillinam was recently FDA approved in April 2024. Briefly describe the mechanism of action of pivmecillinam and its clinical efficacy and safety profile.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
